Category: Clinical Trials

Clinical Trials Healthcare & Pharmaceuticals News

Amgen and Kyowa Kirin Announce Positive Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis

amgen

Amgen and Kyowa Kirin announced positive top-line results from the ASCEND Phase 3 long-term study for rocatinlimab, an investigational treatment for adults and adolescents with moderate to severe atopic dermatitis. The study demonstrated a continued therapeutic benefit and a consistent safety profile, showing sustained improvements in skin clearance and itch reduction at one year.

Clinical Trials News Oncology

AstraZeneca’s Tagrisso Combination Therapy Sets New Survival Benchmark in Advanced Lung Cancer

AstraZeneca

hase III trial called FLAURA2 has demonstrated that the combination of AstraZeneca’s drug, Tagrisso, with chemotherapy has led to a median overall survival of nearly four years for patients with a specific type of advanced lung cancer. This marks the longest survival benefit ever recorded in a global trial for this condition, solidifying Tagrisso as a standard-of-care treatment and providing a new benchmark for patient outcomes.

Clinical Trials Healthcare & Pharmaceuticals News Weight-loss Drugs

Wegovy® Shows Superior Cardiovascular Protection Over Tirzepatide in Real-World Study

novo nordisk

The landmark STEER study provides the first head-to-head real-world comparison of the cardiovascular benefits of Wegovy® and tirzepatide. In a study of over 21,000 adults with obesity and established cardiovascular disease, Wegovy® (semaglutide 2.4 mg) demonstrated a significantly greater reduction in the risk of heart attack, stroke, and death compared to tirzepatide.

Clinical Trials Diabetes News

Lilly’s Oral GLP-1 Orforglipron Achieves Success in Third Phase 3 Trial, Triggering Global Regulatory Submissions

Eli Lilly and Company

Eli Lilly announced results from the Phase 3 ATTAIN-2 trial, where its oral GLP-1 receptor agonist orforglipron provided substantial weight loss and improved A1C for adults living with obesity and type 2 diabetes demonstrating efficacy and safety consistent with injectable medicines, and moving toward regulatory approval.